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Mortality in chronic kidney disease remains high, particularly among the elderly, who represent the most rapidly growing segment
of the end-stage renal disease population in wealthier countries. The management of older adults with chronic kidney disease
has become a clinical challenge, and care for those patients expected to progress to end-stage renal disease should focus on
evaluating the overall benefit of offering renal replacement therapy to them. Predictive mortality models may help to inform shared
decision-making in the trajectory of the elderly with chronic kidney disease.This review discusses current literature on the available
predictive models for predicting survival in elderly chronic kidney disease patients and reflects the author’s own interpretation and
experience.
1. Introduction
The prevalence of chronic kidney disease (CKD) is higher
in older people. Patients over 65 years of age represent the
most rapidly growing segment of the end-stage renal disease
(ESRD) population in wealthier countries [1, 2], as well as
showing a high prevalence of earlier stages of CKD, with rel-
ative prevalence equally striking for populations in the USA,
Canada, and Europe [1, 3–5].
The management of older adults with CKD has become
a clinical challenge, and care for those patients expected to
progress to ESRD should focus on evaluating the overall
benefit of offering renal replacement therapy (RRT) to them.
Although survival may have improved over time for older
patients initiating dialysis [6], this survival benefit in the
elderly is lower as compared to their younger counterparts
[7]. Comparing dialysis versus conservative management,
dialysis may be associated with a very small survival benefit
[8] and associated with a concomitant overall decline in func-
tional and cognitive status [9] andmore hospitalizations [10].
In elderly patients with significant comorbidities, con-
servative management may therefore be a better therapeutic
option, as dialysis is unlikely to prolong or improve quality of
life [11].
Beyond the usual clinical criteria, the RRT decisions in
elderly patients must incorporate assessment of physical and
cognition function and other components of geriatric syn-
drome.
Recently there is a growing interest in developing predic-
tive mortality models to improve patient outcomes through
individualized risk prediction. These predictive models may
help the nephrologist in their discussions with patients and
their families about suitability or otherwise of initiating
dialysis.
This review discusses current literature on the available
predictive models for predicting survival in elderly CKD
patients and reflects the author’s own interpretation and
experience.
2. Risk Prediction Models
2.1. Definition, Performance, and Validation. Risk prediction
models are based on equations designed on the basis of
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prognostic factors and clinical outcomes, available at the
time the prediction is made, and collected in specific and
representative cohorts of individuals followed up for a given
period of time [12, 13]. Each prognostic factor or variable is
awarded a weight (coefficient) and combined in amathemati-
cal formula, the so-called risk equation, to predict an outcome
of interest [12, 13].
The performance of a risk prediction model is commonly
assessed by testing its calibration and discrimination. Cali-
bration describes the agreement of observed and predicted
event rates [14], and discrimination expresses the ability of
prediction model to distinguish individuals who will develop
the outcome of interest from those who will not [15].
The most used measure of discrimination is the C-sta-
tistic, a measure of concordance between model-based risk
estimates and observed events [16–18]. The C-statistic ranges
from 0.5 (random concordance) to a theoretical maximum of
1 (perfect concordance), but it has several limitations [18].
First, as a single number, it summarizes the discrimina-
tion of amodel but does not communicate all the information
and lacks direct clinical application. The C-statistic does not
effectively balance misclassification errors, and a weighted
sum of sensitivity and specificity have more clinical relevance
(predicting an individual who ultimately experiences an
event to be at low risk; predicting an individual who does
not experience an event to be at high risk), according to the
principles of decision analysis [19]. Secondly, the value of the
C-statistic depends not only on themodel being assessed, but
also on the distribution of risk factors in the sample to which
it is applied.
Calibration, the agreement of observed and predicted
outcomes, is most appropriately assessed using a calibration
plot [16], which assesses how accurately the model’s predic-
tions match overall observed event rates. Unfortunately, in
the majority of the studies calibration measures are often
omitted [20, 21].
Another important question for physicians to consider is
whether the score accurately predicts outcomes in people like
their patients. A simple internal validation, that is, a comput-
ing performance measures in the same cohort that has been
used to develop the model, usually leads to overoptimistic
estimates of the performance of a prediction model [13].
Thus, the use of methods such as cross-validation has
been proposed for assessing internal validity. With this
method, the original cohort is split into a development and
a validation sample, to develop the score in one group and
test in the other [13, 22].
Another method that can be used if the number of indi-
viduals in the cohort is relatively low or to avoid false results
caused by one particular random split is the bootstrapping
based on many repeated splits of the data [13, 16, 22].
Even with a good performance measures achieved in the
same cohort as the one that was used to develop the model,
before adopting a risk score into practice, clinicians need
to decide whether the score accurately predicts outcomes in
people like their patients. Therefore, ideally, the model needs
to be tested in a group of people that was not used to develop
the model; it needs to be externally validated [23]; that is,
the performance of the prediction model is tested in patients
with the same disease but belonging to a different source
population.
2.2. Clinical Usefulness. Clinical usefulness may be evaluated
by utility and usability.The utility reflects the extent to which
the risk score actually affects clinical decisions [24]. The
usability reflects the availability of a clinical decision aid, such
as a nomogram or online calculator, which would allow risk
prediction at the bedside [21]. For a risk model to be useful in
practice, it needs to include variables that are well defined,
measurable, and readily available. Finally, information on
outcomes based on these models must be transferred in a
way that is understandable for all involved in shared decision-
making process.
3. Risk Prediction Scoring Models for
Elderly CKD Patients
3.1. Mortality Risk Prediction Models in CKD. In 2013, Tangri
et al. [21] conducted a systematic review to identify prediction
models for kidney failure, cardiovascular events, and all-
cause mortality in CKD patients. They found five studies
(6 models) [25–29] that examined either all-cause mortality
or the composite outcome of kidney failure or death. More
recently, Stryckers et al. [30], in an attempt to construct an
algorithm that helps in planning the care of elderly people
with advanced CKD, identified 4 risk prediction models that
target elderly people with CKD 3–5 [28, 31, 32] and 12 models
developed in elderly with ESRD [33–38].
Looking to the risk models that specifically included
elderly people with CKD, the study of Johnson et al. [28] used
the same variables (age, sex, eGFR, diabetes, hypertension,
and anemia) for both outcomes (RRT or death). They found
that although the same six variables predicted mortality (C-
statistic 0.70) and its composite end of RRT and death (C-
statistic 0.71), the overall prediction was markedly less effec-
tive than for RRT (C-statistic 0.91). They also found an
inverse association between age and hypertension for death
and a direct association for kidney failure. They concluded
that predicting RRT requires a separate risk score, because
predicting the composite endpoint would favor character-
istics that predict mortality, since mortality is much more
common than RRT in elderly patients. These models [28]
were not validated externally, and calibration measures were
not reported.
More recently, Bansal et al. [31] developed a prediction
equation for 5-year risk of mortality for older people with
CKD stages 3–5 not treated with dialysis. The equation
included nine readily available clinical variables (age, sex,
race, eGFR, urine albumin-to-creatinine ratio, smoking,
diabetes mellitus, and history of heart failure and stroke), and
it was externally validated in a large cohort of elderly CKD
patients. This model has an acceptable calibration and dis-
crimination in both the development (C-statistic = 0.72;
95% confidence interval, 0.68 to 0.74) and validation cohort
(C-statistic = 0.69; 95% confidence interval, 0.64 to 0.74).
However, one of the limitations pointed is that the validation
cohort did not fits the frailty phenotype associated with
CKD [39], because the authors enrolled well-functioning
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men and women, and it has been well established that frailty
is an additional risk factor for mortality in CKD patients
[31].
In another model, Weiss et al. [32] developed a risk
predictionmodel in a retrospective cohort of patients aged 65
to 79 and 80 and older with moderate-to-severe CKD (eGFR,
<30mL/min per 1.73m2) to predict mortality at 6 months
and at 2 years.Themodel included sixteen comorbidities and
measures of health and functional status. Although the C-
statistics for each model for both periods (6 months and
at 2 years) indicated a moderate discrimination (0.68–0.69),
once more, this score risk was not externally validated.
In addition, the presence of comorbidities was determined
within administrative databases, and in retrospective data,
which can considerably reduce the predictive performance of
the model.
However, one of the strengths ofWeiss et al. score [32]was
the incorporation of nondisease specific measures including
markers of healthcare use (e.g., hospitalizations) and func-
tional status (e.g., falls, dementia), contrary to the other avail-
able risk prediction models for mortality in adults with CKD
that mainly focus on traditional risk factors.
3.2. Mortality Risk Prediction Models in ESRD. In 2009,
Couchoud et al. [34], using just clinical features, based on
the REIN (French Renal Epidemiology and Information Net-
work) cohort data, predicted 6-month mortality in elderly
(aged 75 and older) with ESRD patients after initiating
dialysis.
Nine risk factors were selected (demographic and base-
line clinical variables), and the score showed good calibra-
tion, as reflected by the concordance between observed and
expected mortality rates in the validation sample, but with
only a moderate discrimination (mean C-statistic 0.70). The
authors pointed out some limitations, namely, a selection bias
due to the imputedmissing data, and the fact that no informa-
tionwas available about ESRDpatients whowere not referred
to nephrologists or did not receive dialysis. Therefore, this
score cannot be generalizable to the entire population of
elderly ESRD patients, particularly to the patients with high
comorbidities and poor conditions, in which this score
cannot replace the clinical judgment. This score can be used
to facilitate discussion with patients and their families, but
not to withhold dialysis [34].
The Couchoud et al. model [34] was further externally
validated in an US population [33], although investiga-
tors modified the score and they concluded that indices
performed poorly with respect to prediction of 6-month
mortality in in older patients with ESRD commencing dialy-
sis.
Since mortality may be high in the first few months after
initiating dialysis, in 2015, in an attempt to improve their
previous prognostic score [34], using the REIN registry,
Couchoud et al. [35] chose to focus on very early mortality
during the first 3 months of dialysis, in patients aged 75 years
and older. They founded that male gender, age over 85 years,
congestive heart failure, severe peripheral vascular disease,
dysrhythmia, severe behavioral disorders, active malignancy,
serum albumin, and impaired mobility were independently
associated with 3-month mortality.
Despite a good calibration and discrimination, thismodel
[35] had some limitations. First, this score was built within
administrative databases. Second and more important, it was
derived from patient population who have initiated RRT and
do not include those who refuse, are not selected for, or do
not survive to dialysis initiation.
Also, focused in early mortality after dialysis initiation (3
months), Thamer et al. [37], using the US Renal Data System
(patients aged ≥ 67 years), validated a score and proposed a
simple risk assessment questionnaire, based on ready avail-
able information (age, low albumin, assistance with daily
living, nursing home residence, cancer, heart failure, and
hospitalization).
This model [37] was not externally validated and only
used data from administrative databases, with no inclusion
of more detailed clinical and psychosocial data, which is
much important in elderly ESRD patients. Moreover, this
model excluded patients who did not choose dialysis and only
included patients with a 2-year previous follow-up.
Floege et al. [40] have published another risk prediction
model developed in European hemodialysis cohort with a
mean age of 64 years old, using objective measurements only
(i.e., no surprise question or dementia). This model was then
validated in an external cohort of the Dialysis Outcomes and
Practices Patterns Study (DOPPS) and exhibited a moderate
discrimination (C-statistic of 0.68 to 0.79).
Nevertheless, the Floege et al. score [40] has not been
developed nor validated in a cohort of elderly dialysis pa-
tients. In addition, because the development cohort includes
only patients who survived the first 3 months, whereas the
validation cohort of DOPPS includes mainly prevalent pa-
tients, it is still not a perfect risk predictor for frail elderly,
in which the risk of short-term mortality is what needs to be
predicted.
Considering the impact of comorbidity for predicting
survival in elderly dialysis patients, Liu et al. [36] modified
the original Charlson Comorbidity Index (CCI) [41] and
developed a new comorbidity index (nCI) for mortality anal-
yses for dialysis patients using administrative data, based on
the comorbid conditions used by the United States Renal
Data System (USRDS). The index was developed using the
2000 US incident dialysis population and validated using
the 1999 and 2001 US incident dialysis populations and the
2000 US prevalent dialysis population. Interestingly, the Liu
et al. comorbidity index [36] includes 11 comorbid conditions
(atherosclerotic heart disease, congestive heart failure, cere-
brovascular accident/transient ischemic attack, peripheral
vascular disease, dysrhythmia, other cardiac diseases, chronic
obstructive pulmonary disease, gastrointestinal bleeding,
liver disease, cancer, and diabetes), but not the age factor,
one of the components of the original CCI. The authors
[36] showed that nCI performance was almost identical to
the individual comorbid conditions regarding model fit,
predictive ability, and effect on inference, and it its results
showed that nCI is a better predictor than the CCI [41].
Actually, age and comorbidities should both be integrated in
a risk prediction tool as major drivers for mortality.
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Cohen et al. [42] developed a prognostic model to deter-
mine the risk of death in dialysis patients by combining
selected variables from the modified CCI (age, presence of
dementia, and peripheral vascular disease) and serum albu-
min with the nephrologist’s answer to the Surprise Question
(“Would I be surprised if this patient died within the next 6
months?”). This simple bedside tool for predicting 6-month
mortality had superior prognostic value than either tool
independently. Although this prognostic model has not been
developed or validated in elderly dialysis patient, it has the
advantage of being available as online calculator (“Surprise
Question Predictor”at http://nephron.com).
However, we can argue that thismodel [42] has the limita-
tions of being based on subjective parameters (i.e., dementia),
difficult to define in a dialysis patients. In addition, the
Surprise Question is highly subjective and variable based on
nephrologist training and knowledge of patient.
Recently, Wick et al. [43] developed a risk score (Alberta
score) that potentially could be used to estimatemortality risk
during the next 6 months for older patient initiating dialy-
sis.
They identify several independent predictors ofmortality,
which include age of 80 years or older, early dialysis ther-
apy, atrial fibrillation, congestive cardiac failure, lymphoma,
metastatic cancer, and hospitalization in the prior 6 months.
They used a large population-based data source (renal
registry data from Alberta, Canada) consisting of incident
hemodialysis and peritoneal dialysis patients in outpatient
settings, which should minimize selection bias.
The incorporation of variables like lymphoma and meta-
static malignancy as mortality predictors; it maybe will add
clinical utility in contexts in which these conditions appear
with reasonable frequency. Moreover, hospitalizations in the
6 months prior to dialysis initiation, like in Thamer score
[37], were also a mortality predictor and probably related to
comorbidity and disease severity.
Although the Alberta score [43] seems to be a rigorously
and useful derived model, it needs to be replicated in an
independent population.
Finally, the Study ofHeart andRenal Protection (SHARP)
CKD-CVD model [44] was developed using data from 9270
patients with moderate-to-severe CKD (including CKD 3B,
4, 5, dialysis, and kidney transplant patients) in the Study of
Heart and Renal Protection (SHARP) [45], followed for an
average of 5 years.Thismodel projects lifetime cardiovascular
event risks, kidney disease progression, and (quality-of-
life adjusted) survival. Higher age, previous cardiovascular
events, and advanced CKD were the main contributors to
increased individual disease risks. The model [44] performs
well in categories of patients by CKD stage in SHARP and
in external CKD cohorts. A user-friendly web interface
(SHARP calculator, available at http://dismod.ndph.ox.ac.uk/
kidneymodel/app/) which also includes projection of health-
care costs is freely available which facilitate model use.
However, one of the limitations of the SHARP CKD-CVD
model was that SHARP cohort [45] excluded patients with
major coronary disease, whereas in routine clinical practice
coronary heart disease is highly prevalent in CKD pa-
tients.
4. The Author’s Experience
Portugal has the highest unadjusted incidence and prevalence
of ESRD among European countries [46] and 67.7% of the
incident dialysis patients, in 2015, were over 65 years with a
mean age of prevalent patients of 66.7 years [47].
The Nephrology Department at Hospital de Santo Anto´-
nio, Centro Hospitalar do Porto, conducted a retrospective
cohort study of patients aged 65 years and over, referred to our
Department, who started dialysis as their first RRT.This study
aimed to identify elderly ESRD patients who have higher
probability of death, early after starting dialysis, and develop
a prognostic scoring model of 6-month mortality. This score
was developed using data from a cohort of 360 patients
who initiated dialysis between 2012 and 2015. Demographics
and clinical variables were included as potential predictors.
Multivariable adjusted logistic regression was used to deter-
mine the independent predictors of 6-month mortality. The
𝛽-coefficients from the final model (backward elimination)
were used to generate point scores for calculating mortality
risk. Then, our score was compared with others previously
validated (Couchoud et al. [34] and Cohen et al. scores
[42]).
In a univariate logistic analysis, the significant predictors
of 6-month mortality were female gender, age > 75 years,
ischemic heart disease, congestive heart failure, dysrhythmia,
low albumin levels, unplanned dialysis, functional depen-
dence, cognitive impairment, and being institutionalized.
These candidate variables were included in a multivariable
analysis and the regression 𝛽-coefficients from the final
model were used to derive point scores to predict a patient’s
risk of dying in the first 6 months after starting dialysis. The
final model for 6-month mortality risk included older age,
female gender, ischemic heart disease, and low albumin levels
(articles submitted or in draft).
Our model does not seem to be weaker than other pub-
lished scores (the area under the receiver operating charac-
teristic curve (AUC) in our score, Couchoud et al. [34] and
Cohen et al. [42] scores were 0.85, 0.73, and, 0.81, resp.).
This simple prediction score based on readily available
clinical and laboratory data can be a practical and useful
tool to assess short-term prognosis in elderly ESRD, although
further research is needed to confirm and validate the use of
this prognostic score.
5. Conclusions
Shared decision-making is a process of communication. It is
particularly relevant when counselling elderly patients and
their families on different RRT treatment options. This pro-
cess may enable us to understand the advantages, limitations,
and burdens, of the different treatment options, including
conservative care.
Reliable, validated risk prediction models that correctly
estimate risk of death after starting RRT may provide a more
accurate perception of the desirability of starting dialysis and
help in shared decision plan. Healthcare workers need to
understand the applicability and limitations of these models
so that they can be used appropriately.
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In addition to the lack of external validation of the
majority of the existing mortality scores, another important
limitation is their inherent selection bias. Mostly, they were
derived from patient populations who have initiated dialysis
therapy and do not include those who are not selected for,
or not accept, or do not survive to dialysis initiation. A score
that evaluates older patients at the point of decision-making,
rather than at the point of starting dialysis, would be more
helpful.
Determining and communicating information prognosis
for individual patients should be a part of clinical practice,
and although the scores risk models cannot replace the
clinical judgment, they are important instruments because
they allow the patient to be aware of the future course of his
disease and help physicians to guide clinical decision.
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